Skip to main content
    E

    enGene Therapeutics Inc. (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.72
    -0.17 (-8.99%)

    Market Cap: $161.51M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    enGene Therapeutics Inc. (ENGN) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    enGene Therapeutics (ENGN) has a latest price of $1.72 on Nov 17, 2026, 86.0% below its 52-week high of $12.25. Its price fell 79.8% over the past 12 months.

    Price Chart

    From Nov 2023 to Oct 2026, its highest month-end close was $16.95 in Mar 2024 and its lowest $1.53 in Oct 2026, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart ENGN with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ENGN.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 7.0%, and over 6 months it rose 12.4%.

    PeriodChange
    1 month+8.9%
    3 months-7.0%
    6 months+12.4%
    12 months-79.8%
    12 months, with dividends-79.8%
    Price change over each period. Dividends are not included unless the row says so.

    Price by Year

    Its best calendar year was 2025, when the price rose 35.8%, and its weakest was 2024, when it fell 28.0%.

    YearCloseChange
    2026 through Oct 2026$1.53-83.1%
    2025$9.03+35.8%
    2024$6.65-28.0%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 3.8% below its 50-day average of $1.79 and 55.5% below its 200-day average of $3.87.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$1.72
    52-week high$12.25-86.0%
    52-week low$1.40+22.9%
    50-day average$1.79-3.8%
    200-day average$3.87-55.5%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 92.1%.

    MeasureValue
    1-year beta2.13
    Largest fall, 1 year-88.2%
    Largest fall, 3 years-92.1%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About ENGN

    What is ENGN's 1-year price change?

    enGene Therapeutics's price fell 79.8% over the past 12 months. With dividends included, the 12-month total return was -79.8%.

    What is ENGN's 52-week high and low?

    enGene Therapeutics's 52-week high is $12.25 and its 52-week low is $1.40. Its latest price of $1.72 on Nov 17, 2026 is 86.0% below the high.

    What is ENGN's beta?

    enGene Therapeutics's 1-year beta against the S&P 500 is 2.13, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 88.2%.

    Is the ENGN chart free?

    Yes. Advanced Charting for ENGN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.